Drug class profile · refreshed daily from federal data

Androgen

7 molecules in this class, $210.9M combined CY2024 Part D spend across 2.6M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Androgen class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $210.9Mcombined across class
Total Rx claims: 2.6M783K unique beneficiaries
Generic mfrs (active): 28across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Testosterone

Brand: AndroGel · 864K Part D claims (CY24) · 251K beneficiaries · First FDA approval: 2002-10-31

14 generic mfrs 1687 plans require PA

Low NADAC$0.406

→

Avg plan cost$26.53

Part D spend $145.9M 65× spread, current vs floor

Class share

69%

of class CY24 spend

View profile →

Testosterone Cypionate

Brand: AZMIRO · 1.7M Part D claims (CY24) · 529K beneficiaries · First FDA approval: 1979-07-25

10 generic mfrs 816 plans require PA

Low NADAC$2.31

→

Avg plan cost$7.82

Part D spend $61.3M 3× spread, current vs floor

Class share

29%

of class CY24 spend

View profile →

Danazol

10K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 1996-08-09

2 generic mfrs 135 plans require PA

Low NADAC$1.56

→

Avg plan cost$2.24

Part D spend $2.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Methyltestosterone

Brand: METHITEST · 193 Part D claims (CY24) · 32 beneficiaries · First FDA approval: 1974-10-17

2 generic mfrs 24 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $917715

Class share

of class CY24 spend

View profile →

Esterified Estrogens and Methyltestosterone

Brand: Estratest FS · — Part D claims (CY24) · First FDA approval: 2010-09-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Esterified Estrogens, Methyltestosterone

Brand: ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE · — Part D claims (CY24) · First FDA approval: 2022-10-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Testosterone Gel,

— Part D claims (CY24) · First FDA approval: 2021-01-10

Brand-only (no generics)

Low NADAC$0.406

→

Avg plan cost$0.812

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.